Personalis, Inc.

We may acquire businesses or assets, form joint ventures, or make investments in other companies or technologies that could harm our operating results, dilute stockholders ownership, or cause us to incur debt or significant expense.

SEC original ↗Personalis, Inc. — 10-Q Quarterly report10-QAug 4, 2026

We do not currently intend to pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation of the value of our common stock.

SEC original ↗Personalis, Inc. — 10-Q Quarterly report10-QAug 4, 2026

The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.

SEC original ↗Personalis, Inc. — 10-Q Quarterly report10-QAug 4, 2026

government securities 82,224 1 ( 92 ) 82,133 Level 2 Total short-term investments 118,809 1 ( 120 ) 118,690 Total assets measured at fair value $ 212,787 $ 1 $ ( 130 ) $ 212,658 December 31, 2025 Adjusted Cost Unrealized Gains Unrealized Losses Fair Value Fair Value Level Assets Cash and cash equivalents: Cash $ 4,919 $ $ $ 4,919 Money market funds 45,349 45,349 Level 1 Commercial paper 498 498 Level 1 Commercial paper 73,491 ( 12 ) 73,479 Level 2 Total cash and cash equivalents 124,257 ( 12 ) 124,245 Short-term investments: Commercial paper 498 498 Level 1 Commercial paper 12,734 ( 2 ) 12,732 Level 2 Corporate debt securities 4,680 1 ( 2 ) 4,679 Level 1 U.

SEC original ↗Personalis, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Discount rates are based on estimates of the Company's incremental borrowing rate, as the discount rates implicit 18 Table of Contents in the leases cannot be readily determined.

SEC original ↗Personalis, Inc. — 10-Q Quarterly report10-QAug 4, 2026

(Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2025, and recent accomplishments of its Win-in-MRD strategy: Second Quarter 2025 and Recent Business Highlights Clinical Adoption Acceleration: Delivered 3,478 clinical tests in the second quarter, a 59% sequential increase over Q1 2025, demonstrating accelerating physician adoption of the NeXT Personal ® platform Commercial Partnership Expansion: Broadened the strategic collaboration with Tempus AI, Inc.

SEC original ↗Personalis, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Notably, nearly half of all positive detections were found in the ultra-sensitive range Clinical Utility Demonstration: Additional data presented at ASCO from the Phase 3 CALLA trial in partnership with AstraZeneca showed NeXT Personal detected cervical cancer progression up to 16 months earlier than standard imaging The results of our Win-in-MRD strategy are clear, with an impressive 59% sequential growth in our clinical test volume, said Chris Hall, Chief Executive Officer and President of Personalis.

SEC original ↗Personalis, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Steady recognition and growth in the use of our platform continues to support our strategy as we navigate the temporary headwinds in the biopharma sector which have affected our current results.

SEC original ↗Personalis, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Our fundamental growth engine is accelerating, keeping us firmly on track to achieve our most critical strategic objectives for 2025, including securing Medicare coverage for two indications.

SEC original ↗Personalis, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development.

SEC original ↗Personalis, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Steady recognition and growth in the use of our platform continues to support our strategy as we navigate the temporary headwinds in the biopharma sector which have affected our current results.

SEC original ↗Personalis, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the timing and pace of new orders from customers, including from ModernaTX, Inc.

SEC original ↗Personalis, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions Risk Factors and Management s Discussion and Analysis of Financial Condition and Results of Operations in Personalis Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, being filed with the SEC later today.

SEC original ↗Personalis, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Legal Proceedings 39 Item 1A.

SEC original ↗Personalis, Inc. — 10-Q Quarterly report10-QAug 4, 2026

The outcome of the events described in these forward-looking statements is subject to risks, uncertainties, assumptions, and other factors described in the section titled Risk Factors and elsewhere in this Quarterly Report on Form 10-Q.

SEC original ↗Personalis, Inc. — 10-Q Quarterly report10-QAug 4, 2026

New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q.

SEC original ↗Personalis, Inc. — 10-Q Quarterly report10-QAug 4, 2026